10-Q: NeuroPace Q2 Revenue Soars 22%, Gross Margin Expands

NeuroPace, Inc. reported a 22% revenue increase and significant gross margin expansion in Q2 2025, alongside strategic debt refinancing and progress in clinical trials for epilepsy treatments.

Summary

• Revenue for the three months ended June 30, 2025, increased by 22% to $23.5 million, up from $19.3 million in the prior year period, primarily driven by increased RNS System unit sales and DIXI Medical product sales.
• Gross profit for the quarter rose by 28% to $18.1 million, with gross margin improving to 77.1% from 73.4% in the same period last year, attributed to higher production volume of the RNS System.
• Net loss for the three months ended June 30, 2025, was $(8.7) million, compared to $(7.5) million in the prior year, while the net loss for the six months ended June 30, 2025, improved to $(15.2) million from $(16.4) million.
• The company completed a follow-on offering in February 2025, raising $69.7 million in net proceeds, of which $49.5 million was used to repurchase shares from KCK Ltd.
• The CRG Term Loan was fully repaid in June 2025 for $61.9 million, including a reduced backend fee of 8%, and replaced with a new $60.0 million MidCap Term Loan and a $15.0 million revolving credit facility, maturing in June 2030.
• Preliminary one-year results from the NAUTILUS study for generalized epilepsy met the primary safety endpoint, but the primary effectiveness endpoint did not reach statistical significance in the overall study, though it did in a majority subset of participants.
• Cash, cash equivalents, and short-term investments totaled $62.1 million as of June 30, 2025, with management believing this is sufficient to fund operations for at least the next 12 months.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth and significant gross margin expansion, coupled with a successful debt refinancing that improves its financial structure and extends maturity. While net losses persist and a key clinical trial endpoint was mixed, the overall financial performance and strategic advancements indicate positive momentum and a strengthened liquidity position.

Positives

• Strong revenue growth of 22% for the quarter and 23% for the six-month period, indicating increasing market adoption of the RNS System.
• Significant improvement in gross margin to 77.1% for the quarter and 77.0% for the six-month period, driven by increased production volume and lower fixed costs per unit.
• Successful refinancing of the CRG Term Loan with a new MidCap Term Loan, resulting in a lower effective interest rate (11.5% vs 13.5-16.8%) and an extended maturity date to June 2030.
• The NAUTILUS study for generalized epilepsy met its primary safety endpoint, confirming the RNS System's favorable safety profile, and showed statistically significant and clinically meaningful results in a subset of participants.
• Expanded commercial efforts targeting epileptologists and functional neurosurgeons outside of Level 4 Comprehensive Epilepsy Centers, following FDA approval of updated qualification criteria.
• Increased cash and cash equivalents to $22.9 million and total liquidity (cash, cash equivalents, and short-term investments) to $62.1 million, providing a stronger financial runway.
• Repurchase of 5,270,845 shares from KCK Ltd. using proceeds from the follow-on offering, which can reduce potential overhang from a significant stockholder.

Negatives

• Net loss for the three months ended June 30, 2025, increased to $(8.7) million from $(7.5) million in the prior year, primarily due to increased operating expenses.
• The primary effectiveness endpoint of the NAUTILUS study for generalized epilepsy did not reach statistical significance in the overall study population, which could impact future label expansion efforts.
• The exclusive distribution agreement with DIXI Medical will expire on September 30, 2025, leading to a loss of associated revenue after a six-month wind-down period.
• Continued reliance on a limited number of single-source suppliers for critical RNS System components, posing supply chain risks.
• The company has a history of net losses and expects to continue incurring losses and negative cash flows from operations for the foreseeable future.

Risks

• Reliance on the RNS System as the primary revenue source, with current marketing limited to adults with drug-resistant focal epilepsy in the U.S.
• Commercial success depends on attaining significant market acceptance and increasing the number of patients treated, both within Level 4 Comprehensive Epilepsy Centers and in the community.
• Dependence on a limited number of single-source suppliers for product components, making the company vulnerable to supply shortages and price fluctuations.
• Inability to accurately forecast customer demand for products, potentially leading to inventory write-downs or shortages.
• Intense competition from other treatment options for drug-resistant focal epilepsy, including ablative/resective surgery and other neuromodulation devices (e.g., LivaNova's VNS System, Medtronic's DBS System).
• Risk of inadequate or unfavorable changes in reimbursement for RNS System implant procedures and ongoing patient care from third-party payors.
• Requirement for appropriate neurosurgeon training for implantation and epileptologist training for programming and ongoing patient care; inadequate training could lead to negative patient outcomes.
• Inability to achieve or maintain satisfactory pricing and margins for the RNS System, potentially harming business and results of operations.
• Uncertainty in obtaining expanded FDA labeling for the RNS System to treat patients with generalized drug-resistant epilepsy and pediatric patients (ages 12-17) with drug-resistant focal epilepsy.
• Potential delays in FDA review of expanded indication applications due to recent staffing changes at the FDA.
• Pervasive and continuing FDA regulatory requirements, with failure to comply potentially leading to enforcement actions.
• Risks related to data privacy and security laws and regulations, including potential breaches or failures of information technology systems.
• Challenges in obtaining, maintaining, protecting, enforcing, and defending patent or other intellectual property protection, or risk of competitors developing similar products.
• History of net losses and expectation to continue incurring losses for the foreseeable future, with no guarantee of sustained profitability.
• Restrictive covenants and financial maintenance covenants in the MidCap Term Loan agreement, with potential for an event of default if not complied with.
• Loss of revenue growth and potential impact on cash flow breakeven due to the planned expiration of the exclusive distribution agreement with DIXI Medical.
• Actual operating results may differ significantly from any guidance provided, leading to stock price volatility.
• Inaccurate estimates of market opportunity and forecasts of market and revenue growth.
• Growth prospects may be harmed if the company is unable to successfully leverage its unique data asset and analysis capabilities.
• Difficulties in obtaining regulatory clearance or approval and successfully marketing the RNS System internationally in the future.
• Potential adverse impact from future legislation, changes in federal regulatory agency leadership, and new policies and priorities.
• Product liability lawsuits could lead to substantial liabilities and require limiting or halting product marketing and sales.
• Failure of third parties (suppliers, vendors, partners, consultants) to meet contractual, regulatory, and other obligations.
• Unstable market and economic conditions, including inflation and interest rate changes, may adversely affect business, financial condition, and share price.
• Business disruptions (e.g., natural disasters, public health crises) could harm future revenue and financial condition.
• Litigation and other legal proceedings may harm the business, reputation, and financial condition.
• If securities or industry analysts do not continue to publish research or publish unfavorable or inaccurate research, the common stock price and trading volume could decline.
• Failure to maintain proper and effective internal control over financial reporting could negatively impact investor confidence.
• Significant costs associated with operating as a public company and compliance with public company responsibilities.
• Risks associated with partnering with or acquiring other businesses, including significant management attention, business disruption, and dilution of stockholder value.

Future Outlook

The company expects to continue incurring net losses and negative cash flows for the near term due to significant investments in research and development, clinical studies, and commercial activities. It plans to file an expanded label submission to the FDA for generalized epilepsy in the second half of 2025 and is collaborating on the RESPONSE study for pediatric focal epilepsy. Management believes existing cash, cash equivalents, and short-term investments will fund operations for at least the next 12 months, but may opportunistically seek additional capital through equity or debt financings.

Management Comments

• The RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source.
• The RNS System is the only commercially available device that records continuous brain activity data and allows clinicians to monitor patients not only in person, but also remotely, providing them the data they need to make more informed treatment decisions, thus optimizing patient care.
• The therapeutic advantages of the RNS System, combined with the insights obtained from our extensive brain data set, offer a significant leap forward in epilepsy treatment.
• The NAUTILUS study met the 12-week post-implant primary safety endpoint, demonstrating excellent safety outcomes and confirming the favorable safety profile of the RNS System.
• Preliminary data from the NAUTILUS trial illustrates the overall value of the RNS System to individualize patient treatment over time, showing statistically significant and clinically meaningful, prespecified secondary endpoints.
• We are actively engaging with the FDA to finalize a pathway to submitting an application seeking the expanded indication for patients with generalized epilepsy.
• There are no changes in the company's plan to file the expanded label submission to the FDA in the second half of 2025.
• We believe that we currently have adequate manufacturing capacity and supplies for our products sufficient to meet our demand forecasts.
• We believe our existing cash, cash equivalents and short-term investments will allow us to continue our operations for at least the next 12 months.

Industry Context

NeuroPace operates in the highly competitive medical device industry, specifically within the neuromodulation and epilepsy treatment sector. The RNS System competes with established neuromodulation devices like LivaNova's VNS System and Medtronic's DBS System, as well as traditional surgical and pharmaceutical treatments. The company's strategy to expand beyond Level 4 Comprehensive Epilepsy Centers into community settings reflects a broader industry trend of increasing access to specialized treatments. The focus on leveraging brain data and AI-enabled software tools aligns with the growing emphasis on personalized medicine and data-driven healthcare solutions. The mixed results of the NAUTILUS study highlight the challenges of clinical development in complex neurological disorders, even as the company maintains its commitment to expanding indications.

Comparison to Industry Standards

• The RNS System's reported efficacy of 82.0% median seizure reduction at 36 months and 22% of patients seizure-free for at least one year demonstrates strong long-term outcomes compared to general epilepsy treatment benchmarks, where drug-resistant epilepsy often means patients fail to achieve sustained seizure freedom after trying two antiseizure medications.
• The RNS System's average battery life of nearly eleven years for its current neurostimulator model is a significant improvement over previous models and potentially competitive with other implanted neuromodulation devices, reducing the frequency of replacement procedures.
• The company's gross margin of 77.1% is robust for a medical device company, indicating efficient manufacturing and strong pricing power, potentially outperforming some industry averages for complex implantable devices.
• The NAUTILUS study's primary safety endpoint being met is a positive indicator, as safety is paramount in implantable medical devices, aligning with high industry standards for patient well-being.
• The company's trailing 12-month net RNS System revenue of $71.6 million as of June 30, 2025, is a key metric for its debt covenants, with a target of $90 million in 2026 to ease liquidity requirements, providing a clear benchmark for future performance relative to its financial obligations.

Management Changes

Legal Proceedings

• The company is not involved in any pending legal proceedings that it believes could have a material adverse effect on its business, results of operations, financial condition, or cash flows.

Related Party Transactions

• Repurchase of 5,270,845 shares of common stock from KCK Ltd., a significant stockholder, for $49.5 million at $9.40 per share, using net proceeds from the follow-on offering.

Stakeholder Impact

• Shareholders: Experienced dilution from the follow-on offering but benefited from a strengthened balance sheet and debt refinancing. The share repurchase from KCK Ltd. may reduce potential selling pressure from a large holder.
• Employees: Changes in key management roles (CFO transition) and potential severance costs for departing personnel. Continued investment in sales and marketing teams indicates growth opportunities.
• Customers (Healthcare Providers/Hospitals): Benefit from continued commercialization efforts and potential expansion of RNS System indications, offering more treatment options for patients. The expiration of the DIXI Medical distribution agreement may require customers to seek alternative suppliers for Stereo EEG products.
• Patients: Continued access to the RNS System for drug-resistant focal epilepsy. Ongoing clinical trials aim to expand treatment options for generalized epilepsy and pediatric patients, potentially improving outcomes for more individuals.
• Creditors: The successful refinancing of debt with MidCap Financial Trust at a lower effective interest rate and extended maturity improves the company's debt profile and reduces near-term repayment pressure. The new credit agreement includes financial covenants that the company must maintain.

Next Steps

• File expanded label submission to the FDA for generalized epilepsy in the second half of 2025.
• Continue patient participation in the NAUTILUS study through the completion of two years after device implant, with prespecified data collection.
• Continue collaboration with NEST and FDA to pursue the use of real-world data from the Pediatric Epilepsy Research Consortium (PERC) for the RESPONSE study.
• Expand outreach to centers and clinicians outside Level 4 Comprehensive Epilepsy Centers through 2025, with incremental expansion of the sales force.
• Wind down the DIXI Medical distribution agreement through the first quarter of 2026, including selling existing inventory and DIXI Medical buying back unsold inventory.
• Continue investing in research and development, clinical studies, and regulatory affairs to support ongoing and future regulatory submissions and product improvements.
• Continue making significant investments in sales and marketing efforts to drive awareness and expand referral channels.

Key Dates

Recommendation

The company demonstrated robust revenue growth and significant gross margin expansion, indicating strong operational performance and increasing market acceptance of its RNS System. The successful refinancing of its debt at more favorable terms and extended maturity significantly improves its financial stability and liquidity. While the NAUTILUS study's primary effectiveness endpoint was mixed, the positive safety profile and continued pursuit of FDA label expansion for generalized epilepsy, alongside pediatric indications, present substantial long-term growth opportunities. The company's strengthened cash position from the follow-on offering provides a runway for continued investment in R&D and commercialization, making it an attractive long-term investment in a specialized medical device market.

Keywords

Neuromodulation, Epilepsy Treatment, RNS System, Medical Device, Drug-Resistant Epilepsy, Focal Epilepsy, Generalized Epilepsy, FDA Approval, Clinical Trials, Financial Results, SEC Filing, 10-Q, Revenue Growth, Gross Margin, Debt Refinancing, Capital Raise, Biomarker Monitoring, AI-enabled Software, Healthcare Technology